{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:11:23Z","timestamp":1782832283888,"version":"3.54.5"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Cervical cancer is the second leading cause of cancer-related death among women in Mexico, accounting for approximately 4,500 deaths annually. The Mexican Social Security Institute (IMSS), which provides mandatory social security and healthcare for formal-sector workers, currently relies on conventional cervical cytology for early detection. To explore alternatives, a workplace-based pilot program introducing human papillomavirus (HPV) self-sampling was implemented. This study compares the effectiveness and feasibility of HPV self-sampling with the existing cytology program, aiming to inform future screening strategies. A prospective analysis of the cost-saving impact was conducted from the IMSS institutional financing perspective, including healthcare program costs and IMSS-financed disability leave and pension payments. A two-module Markov model separately simulated clinical pathways for detection, diagnosis, and treatment under each screening strategy, and the natural progression of HPV infection and cervical intraepithelial neoplasia. Model inputs were derived from the HPV self-sampling pilot and complementary literature. Costs are reported in 2024 USD and both costs and outcomes are discounted at 3% annually. Both programs were evaluated by simulating a cohort of 100,000 women over a 10 year period. The HPV self-sampling strategy was less costly and more effective than cytology. In the modeled cohort, HPV screening prevented 812 cervical cancer cases at a total cost of 39.7 million USD, resulting in a cost of 48,896 USD per cancer case prevented. In contrast, the cytology program prevented 651 cases at a cost of 99.9 million USD, yielding 153,559 USD per case prevented. HPV self-sampling demonstrated a 61% increase in the detection of high-grade cervical lesions and was less costly and more effective than cytology. The reduction in disability leaves and associated social security expenditures further amplifies its economic value for an institution like IMSS. These findings highlight the potential benefits of increasing screening coverage and implementing workplace-based HPV screening.<\/jats:p>","DOI":"10.1371\/journal.pgph.0006389","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:44:06Z","timestamp":1777916646000},"page":"e0006389","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["The cost-saving impact of human papillomavirus self-sampling for cervical cancer screening in women workers at the manufacturing sector in Ciudad Ju\u00e1rez, Chihuahua, Mexico"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-5134","authenticated-orcid":true,"given":"Olga Georgina","family":"Mart\u00ednez Monta\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1555-0841","authenticated-orcid":true,"given":"Francisco Javier","family":"Pic\u00f3-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1057-424X","authenticated-orcid":true,"given":"Gerardo Garc\u00eda","family":"Zavaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio Rafael","family":"Tinoco V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0297-7964","authenticated-orcid":true,"given":"Jos\u00e9 Antonio","family":"Zamudio Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0393-7590","authenticated-orcid":true,"given":"Mauricio Hern\u00e1ndez","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"pgph.0006389.ref001","unstructured":"Modificaci\u00f3n a la Norma Oficial Mexicana NOM-014-SSA2-1994, Para la prevenci\u00f3n, detecci\u00f3n, diagn\u00f3stico, tratamiento, control y vigilancia epidemiol\u00f3gica del c\u00e1ncer c\u00e9rvico uterino. Available from: https:\/\/www.dof.gob.mx\/normasOficiales\/2383\/SALUD\/SALUD.htm"},{"key":"pgph.0006389.ref002","first-page":"549","article-title":"Tamizaje del c\u00e1ncer cervical","volume":"66","author":"LS Le\u00f3n-Maldonado","year":"2024","journal-title":"Salud Publica Mex"},{"key":"pgph.0006389.ref003","unstructured":"INEGI. Estad\u00edsticas a prop\u00f3sito del D\u00eda Mundial contra el C\u00e1ncer. Comunicado de Prensa [Internet]. 2025 [cited 2025 Mar 31]. Available from: 2025 https:\/\/www.inegi.org.mx\/contenidos\/saladeprensa\/aproposito\/2025\/EAP_DMvsCancer25.pdf"},{"key":"pgph.0006389.ref004","unstructured":"All.Can: M\u00e9xico. Informe ejecutivo sobre las tendencias de mortalidad por c\u00e1ncer en M\u00e9xico a nivel nacional. [Internet]. 2022 [cited 2025 Mar 31]. Available from: https:\/\/funsalud.org.mx\/wp-content\/uploads\/2022\/07\/Informe_Tendencia-Mortalidad-Ca-ncer-Me%CC%81xico-vFinalwww-280622.pdf"},{"key":"pgph.0006389.ref005","doi-asserted-by":"crossref","first-page":"1008560","DOI":"10.3389\/fonc.2023.1008560","article-title":"Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunities","volume":"13","author":"A Cruz-Valdez","year":"2023","journal-title":"Front Oncol"},{"key":"pgph.0006389.ref006","unstructured":"IMSS. Informe al Ejecutivo Federal y al Congreso de la Uni\u00f3n sobre la Situaci\u00f3n Financiera y los Riesgos del Instituto Mexicano Del Seguro Social 2024-2025 Available from: https:\/\/www.imss.gob.mx\/sites\/all\/statics\/pdf\/informes\/20242025\/19-informe-completo.pdf"},{"key":"pgph.0006389.ref007","unstructured":"IMSS. Indicadores, datos y estad\u00edsticas; informaci\u00f3n en Salud. Tableros de informaci\u00f3n. Portal de Indicadores M\u00e9dicos. CACU_01_2023 [Internet]. [cited 2025 Apr 24]. Available from: http:\/\/intranet\/datos\/Paginas\/infosalud.aspx"},{"issue":"1","key":"pgph.0006389.ref008","doi-asserted-by":"crossref","first-page":"2483018","DOI":"10.1080\/21645515.2025.2483018","article-title":"Barriers and facilitators to a combined strategy of HPV vaccination and cervical cancer screening among Mexican women","volume":"21","author":"L Le\u00f3n-Maldonado","year":"2025","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"pgph.0006389.ref009","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13643-022-02017-z","article-title":"A systematic review of economic evaluations of cervical cancer screening methods","volume":"11","author":"T Sefuthi","year":"2022","journal-title":"Syst Rev"},{"key":"pgph.0006389.ref010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106900","article-title":"Worldwide use of HPV self-sampling for cervical cancer screening","volume":"154","author":"B Serrano","year":"2022","journal-title":"Prev Med (Baltim)"},{"key":"pgph.0006389.ref011","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses","volume":"363","author":"Collaboration on Self-Sampling and HPV Testing","year":"2018","journal-title":"BMJ"},{"issue":"6","key":"pgph.0006389.ref012","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.3390\/curroncol30060425","article-title":"Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations","volume":"30","author":"T Zigras","year":"2023","journal-title":"Curr Oncol"},{"issue":"1","key":"pgph.0006389.ref013","doi-asserted-by":"crossref","DOI":"10.1186\/s12905-022-02043-y","article-title":"Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review","volume":"22","author":"Z Petersen","year":"2022","journal-title":"BMC Women\u2019s Health"},{"issue":"5","key":"pgph.0006389.ref014","doi-asserted-by":"crossref","first-page":"365","DOI":"10.23736\/S0026-4784.19.04468-X","article-title":"Optimizing high risk HPV-based primary screening for cervical cancer in low- and middle-income countries: opportunities and challenges","volume":"71","author":"SA Pimple","year":"2019","journal-title":"Minerva Ginecol"},{"key":"pgph.0006389.ref015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106076","article-title":"Introduction of HPV testing for cervical cancer screening in Central America: the Scale-Up project","volume":"135","author":"F Holme","year":"2020","journal-title":"Prev Med (Baltim)"},{"issue":"3","key":"pgph.0006389.ref016","doi-asserted-by":"crossref","first-page":"103316","DOI":"10.1016\/j.arcmed.2025.103316","article-title":"Evaluation of the Pilot Human Papillomavirus Self-Sampling Program in Workplaces in Ciudad Ju\u00e1rez, Mexico","volume":"57","author":"SV Doubova","year":"2026","journal-title":"Arch Med Res"},{"key":"pgph.0006389.ref017","unstructured":"IMSS. Puestos de trabajo registrados patrones ante el IMSS y su salario registrado, periodo 202501 [Internet]. 2025 [cited 2025 Mar 31]. Available from: https:\/\/public.tableau.com\/app\/profile\/imss.cpe\/viz\/TAPatrones\/Patrones"},{"key":"pgph.0006389.ref018","unstructured":"NORMA Oficial Mexicana NOM-024-SSA3-2010, Que establece los objetivos funcionales y funcionalidades que deber\u00e1n observar los productos de Sistemas de Expediente Cl\u00ednico Electr\u00f3nico para garantizar la interoperabilidad, procesamiento, interpretaci\u00f3n, confidencialidad, seguridad y uso de est\u00e1ndares y cat\u00e1logos de la informaci\u00f3n de los registros electr\u00f3nicos en salud. https:\/\/www.dof.gob.mx\/normasOficiales\/4151\/salud\/salud.htm"},{"key":"pgph.0006389.ref019","unstructured":"WHO. Public report for cobas HPV (PQDx 0468-046-00) Available from: https:\/\/extranet.who.int\/prequal\/WHOPR\/public-report-cobas-hpv-pqdx-0468-046-00"},{"key":"pgph.0006389.ref020","unstructured":"IMSS. Indicadores, datos y estad\u00edsticas; Informaci\u00f3n en Salud. Poblaci\u00f3n Adscrita por Delegaci\u00f3n Noviembre 2024 [Internet]. 2024 [cited 2025 Apr 24]. Available from: http:\/\/intranet\/datos\/Paginas\/infosalud.aspx"},{"key":"pgph.0006389.ref021","unstructured":"World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022: estimated cancer incidence, mortality and prevalence worldwide in 2022. [Internet]. 2022 [cited 2025 Apr 24]. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/maps-prevalence?mode=population&cancers=23&populations=987_988_989_990&multiple_populations=1&options_indicator=%5Bobject%20Object%5D_%5Bobject%20Object%5D&types=2&age_start=6&prev_time=5"},{"key":"pgph.0006389.ref022","unstructured":"Ministry of Health. DGIS. INEGI\/SS. Mortality databases 1998-2023, C53 [Internet]. Mexico and Ciudad Ju\u00e1rez, Chihuahua; 2023 [cited 2025 Apr 24]. Available from: http:\/\/www.dgis.salud.gob.mx\/contenidos\/basesdedatos\/bdc_defunciones_gobmx.html"},{"key":"pgph.0006389.ref023","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.12659\/MSM.895227","article-title":"Analysis of Sensitivity, Specificity, and Positive and Negative Predictive Values of Smear and Colposcopy in Diagnosis of Premalignant and Malignant Cervical Lesions","volume":"21","author":"MU Barut","year":"2015","journal-title":"Med Sci Monit"},{"issue":"2","key":"pgph.0006389.ref024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279728","article-title":"High sensitivity and specificity rates of cobas\u00ae HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting","volume":"18","author":"LA Fleider","year":"2023","journal-title":"PLoS One"},{"issue":"6","key":"pgph.0006389.ref025","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1128\/JCM.00181-12","article-title":"Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study","volume":"50","author":"A Szarewski","year":"2012","journal-title":"J Clin Microbiol"},{"key":"pgph.0006389.ref026","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez AT, Valls J, Baena A, Rojas F D, Ram\u00edrez K, \u00c1lvarez R, et al. Performance of cervical cytology and HPV testing for primary cervical cancer screening in Latin America: an analysis within the ESTAMPA study on behalf of the ESTAMPA Study Group [Internet]. 2023. Available from: www.thelancet.com","DOI":"10.1016\/j.lana.2023.100593"},{"key":"pgph.0006389.ref027","article-title":"Neoplasia intraepitelial cervical, an\u00e1lisis de las caracter\u00edsticas cl\u00ednico-patol\u00f3gicas","volume":"13","author":"EA Medina-Villase\u00f1or","year":"2014","journal-title":"Gaceta Mexicana de Oncolog\u00eda"},{"issue":"1","key":"pgph.0006389.ref028","first-page":"76","article-title":"Survival analysis and associated factors in patients with cervical cancer financed by the Seguro Popular in Mexico","volume":"64","author":"S Torreglosa-Hern\u00e1ndez","year":"2022","journal-title":"Salud Publica Mex"},{"key":"pgph.0006389.ref029","unstructured":"Tratamiento del c\u00e1ncer cervicouterino en segundo y tercer nivel de atenci\u00f3n. Ciudad de M\u00e9xico: Instituto Mexicano del Seguro Social, 16\/03\/2017. Available from: https:\/\/www.imss.gob.mx\/sites\/all\/statics\/guiasclinicas\/333GER.pdf"},{"key":"pgph.0006389.ref030","unstructured":"INEGI. Calculadora de Inflaci\u00f3n. \u00cdndice Nacional de Precios al Consumidor (2024) [Internet]. 2024 [cited 2025 Apr 24]. Available from: https:\/\/www.inegi.org.mx\/app\/indicesdeprecios\/calculadorainflacion.aspx"},{"key":"pgph.0006389.ref031","unstructured":"IMSS. Grupos relacionados con el diagn\u00f3stico: producto hospitalario GRD-IMSS: 2017. [Internet]. 2017 [cited 2025 Apr 24]. Available from: https:\/\/imss.gob.mx\/sites\/all\/statics\/profesionalesSalud\/economia\/Libro-GRD2017.pdf"},{"issue":"5","key":"pgph.0006389.ref032","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.31557\/APJCP.2019.20.5.1547","article-title":"Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City","volume":"20","author":"V Granados-Garc\u00eda","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"pgph.0006389.ref033","doi-asserted-by":"crossref","DOI":"10.1200\/GO.24.00066","article-title":"Toward a framework to assess the financial and economic burden of cervical cancer in low- and middle-income countries: A systematic review","author":"A Fuady","year":"2024","journal-title":"JCO Glob Oncol"},{"issue":"2","key":"pgph.0006389.ref034","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2006.12.010","article-title":"The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study","volume":"105","author":"S Arrossi","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"pgph.0006389.ref035","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41598-024-53878-4","article-title":"Productivity losses from short-term work absence due to neoplasms in Poland","volume":"14","author":"B \u0141yszczarz","year":"2024","journal-title":"Sci Rep"},{"key":"pgph.0006389.ref036","unstructured":"World Population Review. Average Age of Having First Child by Country 2025 [Internet]. 2025. Available from: https:\/\/worldpopulationreview.com\/country-rankings\/average-age-of-having-first-child-by-country"},{"key":"pgph.0006389.ref037","unstructured":"INEGI. Esperanza de vida al nacimiento por entidad federativa seg\u00fan sexo, serie anual de 2010 a 2025 [Internet]. 2025. Available from: https:\/\/www.inegi.org.mx\/app\/tabulados\/interactivos\/?pxq=Mortalidad_Mortalidad_09_b87a4bf1-9b47-442a-a5fc-ee5c65e37648"},{"key":"pgph.0006389.ref038","unstructured":"World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. 2020 [cited 2025 Apr 24]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107"},{"issue":"1","key":"pgph.0006389.ref039","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ygyno.2019.01.021","article-title":"Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland","volume":"153","author":"P Vassilakos","year":"2019","journal-title":"Gynecol Oncol"},{"key":"pgph.0006389.ref040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/1471-2407-11-239","article-title":"Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study","volume":"11","author":"J-F Shi","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"pgph.0006389.ref041","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1186\/s12885-020-07085-9","article-title":"Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study","volume":"20","author":"R Aarnio","year":"2020","journal-title":"BMC Cancer"},{"issue":"12","key":"pgph.0006389.ref042","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41591-023-02600-4","article-title":"Benefits, harms and cost-effectiveness of cervical screening, triage and treatment strategies for women in the general population","volume":"29","author":"KT Simms","year":"2023","journal-title":"Nat Med"},{"key":"pgph.0006389.ref043","unstructured":"Demke O. Clinton health access initiative. Affordability of Screen and Treat Tools for Cervical Cancer. 2024."},{"issue":"4","key":"pgph.0006389.ref044","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2024.103009","article-title":"HPV self-sampling in the workplace: a qualitative study of benefits, barriers, and opportunities for improvement perceived by health professionals and managers","volume":"55","author":"SV Doubova","year":"2024","journal-title":"Arch Med Res"},{"issue":"1","key":"pgph.0006389.ref045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijgo.12773","article-title":"The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador","volume":"145","author":"NG Campos","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"pgph.0006389.ref046","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015048","article-title":"Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua","volume":"7","author":"NG Campos","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"pgph.0006389.ref047","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1038\/s41598-023-29255-y","article-title":"Validity and acceptance of self vs conventional sampling for the analysis of human papillomavirus and Pap smear","volume":"13","author":"MJ Gibert","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"pgph.0006389.ref048","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-023-02288-6","article-title":"Community-integrated self-collected HPV-based cervix screening in a low-resource rural setting: a pragmatic, cluster-randomized trial","volume":"29","author":"A Gottschlich","year":"2023","journal-title":"Nat Med"},{"issue":"5","key":"pgph.0006389.ref049","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41416-022-02094-w","article-title":"Offering HPV self-sampling kits: an updated meta-analysis of the effectiveness of strategies to increase participation in cervical cancer screening","volume":"128","author":"S Costa","year":"2023","journal-title":"Br J Cancer"},{"key":"pgph.0006389.ref050","unstructured":"National Cancer Institute. Cancer Healthcast: NCI Cervical Cancer \u2018Last Mile\u2019 Initiative [Internet]. 2023 [cited 2025 Mar 31]. Available from: https:\/\/prevention.cancer.gov\/major-programs\/nci-cervical-cancer-last-mile-initiative"},{"issue":"5","key":"pgph.0006389.ref051","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ijc.35289","article-title":"Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and\/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial","volume":"156","author":"L Verhoef","year":"2025","journal-title":"Int J Cancer"},{"issue":"7","key":"pgph.0006389.ref052","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/JCM.02570-10","article-title":"Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6\/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test","volume":"49","author":"M Benevolo","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"3","key":"pgph.0006389.ref053","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/aogs.14121","article-title":"Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology","volume":"100","author":"LT Thomsen","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"pgph.0006389.ref054","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"FX Bosch","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"pgph.0006389.ref055","doi-asserted-by":"crossref","first-page":"948471","DOI":"10.3389\/fonc.2022.948471","article-title":"Recent HPV self-sampling use for cervical cancer screening in Latin America and Caribbean: a systematic review","volume":"12","author":"CB Dartibale","year":"2022","journal-title":"Front Oncol"},{"key":"pgph.0006389.ref056","article-title":"Implementation of HPV testing in Latin America","author":"J Jeronimo","year":"2016","journal-title":"J Clin Virol"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:44:13Z","timestamp":1777916653000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0006389"}},"subtitle":[],"editor":[{"given":"Angela","family":"Devine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0006389","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}